April 30, 2014 / 1:35 PM / 3 years ago

Shire says new dry-eye drug fails to meet trial goal

LONDON, April 30 (Reuters) - Drugmaker Shire said on Wednesday that its Lifitegrast treatment for adults with dry eye disease failed to meet one of two goals in a late-stage trial, the same result it saw in trial results in December.

The drug met one goal for patient-reported symptoms of dry eye compared with placebo, the company said, but did not meet the second target based on signs of corneal staining.

Lifitegrast - a potential competitor for Allergan’s Restasis, which is expected to have sales of around $900 million this year - is viewed as a key new product for Shire as it seeks to diversify its product line-up.

Reporting by Paul Sandle; Editing by Brenda Goh

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below